Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases

Experimental Hematology

Volumn 41, Issue 3, 2013, Pages 271-280.e4

  Polzer, Harald ^a,b   Janke, Hanna ^a,b   Schmid, Diana ^a,b   Hiddemann, Wolfgang ^a,b   Spiekermann, Karsten ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CASITAS B LINEAGE LYMPHOMA GENE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EXON; GENE; GENE DELETION; GENE MUTATION; INTERNALIZATION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84874988109     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.016     Document Type: Article

References (42)

1. Schmidt M.H., Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005, 6:907-918.
2. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2:294-307.
3. Ryan P.E., Davies G.C., Nau M.M., Lipkowitz S. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci 2006, 31:79-88.
4. Tan Y.H., Krishnaswamy S., Nandi S., et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 2010, 5:e8972.
5. Loh M.L., Sakai D.S., Flotho C., et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114:1859-1863.
6. Jankowska A.M., Makishima H., Tiu R.V., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood 2011, 118:3932-3941.
7. Kohlmann A., Grossmann V., Klein H.U., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010, 28:3858-3865.
8. Grand F.H., Hidalgo-Curtis C.E., Ernst T., et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113:6182-6192.
9. Dunbar A.J., Gondek L.P., O'Keefe C.L., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68:10349-10357.
10. Muramatsu H., Makishima H., Jankowska A.M., et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010, 115:1969-1975.
11. Makishima H., Jankowska A.M., McDevitt M.A., et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011, 117:e198-e206.
12. Sargin B., Choudhary C., Crosetto N., et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007, 110:1004-1012.
13. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
14. Kales S.C., Ryan P.E., Nau M.M., Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010, 70:4789-4794.
15. Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312.
16. Zheng N., Wang P., Jeffrey P.D., Pavletich N.P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000, 102:533-539.
17. Bonita D.P., Miyake S., Lupher M.L., Langdon W.Y., Band H. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol Cell Biol 1997, 17:4597-4610.
18. Hunter S., Burton E.A., Wu S.C., Anderson S.M. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 1999, 274:2097-2106.
19. Rosnet O., Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 1993, 4:595-613.
20. Masson K., Heiss E., Band H., Ronnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem J 2006, 399:59-67.
21. Xiong Y., Song D., Cai Y., Yu W., Yeung Y.G., Stanley E.R. A CSF-1 Receptor Phosphotyrosine 559 Signaling Pathway Regulates Receptor Ubiquitination and Tyrosine Phosphorylation. J Biol Chem 2011, 286:952-960.
22. Rosenkranz S., Ikuno Y., Leong F.L., et al. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 2000, 275:9620-9627.
23. Kong-Beltran M., Seshagiri S., Zha J., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006, 66:283-289.
24. Reindl C., Quentmeier H., Petropoulos K., et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009, 15:2238-2247.
25. Webb J.L. Effect or more than one inhibitor 1963, Academic Press, New York.
26. Abbas S., Rotmans G., Lowenberg B., Valk P.J. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008, 93:1595-1597.
27. Caligiuri M.A., Briesewitz R., Yu J., et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007, 110:1022-1024.
28. Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003, 17:120-124.
29. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
30. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010, 116:2429-2437.
31. Fernandes M.S., Reddy M.M., Croteau N.J., et al. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 2010, 285:32596-32605.
32. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
33. Nyakern M., Tazzari P.L., Finelli C., et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006, 20:230-238.
34. Kornblau S.M., Womble M., Qiu Y.H., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-2365.
35. Tamburini J., Elie C., Bardet V., et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007, 110:1025-1028.
36. Kharas M.G., Okabe R., Ganis J.J., et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010, 115:1406-1415.
37. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
38. Zeng S., Xu Z., Lipkowitz S., Longley J.B. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 2005, 105:226-232.
39. Vempati S., Reindl C., Wolf U., et al. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res 2008, 14:4437-4445.
40. Jiang X., Huang F., Marusyk A., Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 2003, 14:858-870.
41. Rohde C.M., Schrum J., Lee A.W. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J Biol Chem 2004, 279:43448-43461.
42. Scott R.P., Eketjall S., Aineskog H., Ibanez C.F. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 2005, 280:13442-13449.